243 related articles for article (PubMed ID: 32008868)
21. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
22. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
23. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
24. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
25. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid].
Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY
Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357
[No Abstract] [Full Text] [Related]
26. Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall.
Askan G; Basturk O
Turk Patoloji Derg; 2021; 37(2):115-120. PubMed ID: 33432559
[TBL] [Abstract][Full Text] [Related]
27. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
[TBL] [Abstract][Full Text] [Related]
28. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
29. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
30. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
31. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
32. Diffuse intrapulmonary mesothelioma mimicking pulmonary lepidic adenocarcinoma: a rare case report and review of the literature.
RanYue W; ChunYan W; Likun H; LiPing Z; JieLu L; ZhengWei D
Diagn Pathol; 2023 May; 18(1):64. PubMed ID: 37194050
[TBL] [Abstract][Full Text] [Related]
33. CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma.
Watanabe M; Higashi T; Ozeki K; Higashi AY; Sugimoto K; Mine H; Takagi H; Ozaki Y; Muto S; Okabe N; Matsumura Y; Hasegawa T; Shio Y; Suzuki H; Chiba H
Sci Rep; 2021 Jun; 11(1):12554. PubMed ID: 34131154
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
36. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
37. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
38. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
40. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]